About this episode
Barbell Medicine Q&A: Cholesterol, Hypertrophy Volume, and Training EfficiencyEpisode SummaryIn this Q&A session, Dr. Jordan Feigenbaum addresses listener questions on optimizing training, managing health metrics, and navigating supplement use. Key topics include the latest evidence on cholesterol management (statins vs. PCSK9 inhibitors), why routine Vitamin D supplementation is usually unnecessary, and the mechanics of hypertrophy, emphasizing that volume is superior to intensity once a functional threshold is met. Dr. Feigenbaum also offers practical coaching advice on dynamic volume regulation, the importance of efficiency in the deadlift, and why training models like Pilates do not offer the same benefits as traditional strength work.⏱️ Episode Timestamps00:00 Introduction00:43 Cholesterol Lowering Medication (Statins vs. PCSK9 Inhibitors)03:27 Volume vs. Intensity for Hypertrophy06:48 Regulating Training Volume and the 5% Rule11:43 Barbell Medicine Supplement Philosophy and Safety14:14 Pilates as a Training Modality16:31 Is Zone 2 Cardio Really That Amazing?⭐ Get More Value: Exclusive Content and ResourcesWant to support the show and get early, ad-free access to all episodes plus exclusive bonus content? Subscribe to Barbell Medicine Plus and get ad-free listening, product discounts, and more. Try it free for 30-days.Unsure which training plan is right for you? Take the free Barbell Medicine Template Quiz to be matched with the ideal program for your goals and experience level.For media, support, or general questions, please contact us at support@barbellmedicine.com⚕️ Section I: Clinical and Healthspan OptimizationCholesterol Management: The Lower is Better PhilosophyThe core principle of managing atherogenic risk is that the risk of heart disease is proportional to the overall lifetime exposure (level $\times$ duration) to atherogenic lipoproteins, specifically LDL, triglycerides, and particles tagged with Apolipoprotein B (ApoB). These particles constitute the "atherogenic load."Lowering this load is beneficial, and the data suggests that lower is better for cardiovascular health. While powerful medications like PCSK9 inhibitors offer an immense magnitude of cholesterol lowering and are proven for both primary and secondary prevention of major adverse cardiac events, the general population will often achieve substantial risk reduction with statins or statin/ezetimibe combinations, which are more accessible and cost-effective.This approa
